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INTRODUCTION
Peripheral arterial disease (PAD) is characterised by partial
or complete atherosclerotic obstruction of the arteries of the
lower extremities. It is estimated that more than 200 million
people have PAD worldwide, with a spectrum of symptoms
from none to severe (Fowkes et al., 2013).
Prevalence and incidence of PAD are both sharply age-
related, increasing to more than 10% among patients in their
60s and 70s. Annual incidence of PAD among men reaches
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Patients with peripheral arterial disease (PAD) have substantially impaired health-related quality
of life (HR-QoL). Chronic lower limb ischaemia due to the atherosclerotic occlusion of infra-ingui-
nal arteries is one of the most important causes of invalidity among smokers over the age of fifty.
Historically, these lesions were treated by open bypass surgery. Less invasive endovascular
revascularisation methods are available to treat short lesions, while treatment of long lesions are
lacking. Fully endovascular trans-venous femoro-popliteal bypass (PQ Bypass, Inc., Sunnyvale,
CA, USA) to treat long femoral lesions has been developed recently. The objective of the study
was to evaluate duplex ultrasound (DUS) as a tool to follow up patients after PQ bypass proce-
dure. A prospective clinical study was conducted at one clinical site. DUS of treated arteries and
femoral vein was performed before the procedure, 30 days, 6 months, and 12 months in follow-up
period by 2 independent radiologists. Ankle-brachial index (ABI) evaluation was performed at all
visits. Thirty-five patients (35 limbs) treated with PQ bypass were enrolled in the study. Median
age was 63.6 years (ranged 50 to 87 years). There was 100% successful evaluation of all pa-
tients at all clinical visits available. Deviation of the DUS results was found within the accepted
standard limit between two radiologists. Twelve months after the PQ procedure, 28 (80.0%) PQ
stent-grafts were still functioning without DUS signs of stenosis, while seven (20.0%) limbs expe-
rienced varying degrees of stent malfunction. PQ stent-graft occlusion was detected in five
(14.3%) – 1 (2.9%) patients at one-month follow-up, 3 (8.6%) at six months and 1 (2.9%) at
twelve months follow-up period, respectively. PQ stent-graft proximal junction stenosis was de-
tected in one patient (2.9%) at six months and distal junction stenosis in one patient (2.9%) at
twelve months follow-up, respectively. Despite of graft occlusion found with DUS, two patients
had no severe worsening of post-operative ABI. DUS is a reliable method to evaluate patients af-
ter PQ bypass procedure and has higher sensitivity than ABI to follow-up patients after PQ proce-
dure, especially in asymptomatic stent stenosis. Regular and timely use of DUS during the
postoperative period may help to recognise potential complications and provide effective treat-
ment..
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1.7 per 1000 at the age of 40 to 54 years, 1.5 per 1000 at the
age of 55 to 64, and 17.8 per 1000 at the age of 65 (Hoii et
al., 2001).
Chronic lower limb ischaemia due to the occlusion of
infra-inguinal arteries of atherosclerotic genesis is one of
the most important causes of invalidity among smokers over
the age of fifty. Patients with PAD have substantially im-
paired health-related quality of life (HR-QoL) (Van Hattum
et al., 2011).
Intermittent claudication is the first symptom of the disease,
and non-invasive measures, such as the ankle-brachial index
(ABI), show that asymptomatic PAD is several times more
common in the population than intermittent claudication
(Aboyans et al., 2008).
It should be stressed, that in 15–20% of cases chronic lower
limb ischaemia progresses to critical limb ischaemia (CLI),
characterised by rest pain, ischemic ulcers and gangrene
(Criqui et al., 2015).
Historically, peripheral arterial occlusions in lower extremi-
ties were treated by open bypass surgery. Nowadays, thanks
to the rapid development of technologies, different endovas-
cular revascularisation methods are available for the treat-
ment of femoro-popliteal arterial lesions. Stents or stent
grafts are used to support the result obtained during percuta-
neous angioplasty.
Existing endovascular technologies have a well-documented
success rate with TASC A (Trans Atlantic Inter-Societal
Consensus) and TASC B lesions of femoral artery. Longer
TASC C and TASC D lesions, as well as lesions with com-
plicated and extensive calcification and chronic total occlu-
sion of the superficial femoral artery (SFA) have a much
lower success rate. Thus, new concept PQ bypass was de-
veloped to treat long lesions.
Percutaneous PQ bypass procedure is designed to treat long
femoral artery lesions and to achieve the same end result as
open bypass surgery (Krievins et al., 2018). A specially de-
signed stent for this procedure, the TORUS stent graft sys-
tem, is an expanded polytetrafluorethylene (ePTFE) covered
self-expanding nitinol stent intended to restore blood flow
in femoral artery. Regular stents were usually placed di-
rectly in the lumen of the diseased artery. In contrast, PQ
bypass utilises the femoral vein as a conduit for the stent.
Subsequently, deep venous thrombosis does not allow (ex-
clude) the usage of PQ bypass for purely technical reasons.
PQ procedure has not been performed in patients with hae-
modynamically significant stenosis of femoral vein (Fig. 1).
Nowadays evaluate duplex ultrasound (DUS) and ankle-
brachial index (ABI) are standard non-invasive first-line ex-
aminations in patients with PAD. No data have been re-
ported so far on studies using DUS to evaluate PQ bypass in
patients with long femoral artery occlusions (mean 37 cm),
as was conducted in our study. The goal of our study was to
evaluate the use of DUS in post-procedural follow-up of pa-
tients after PQ bypass.
PATIENTS AND METHODS
Thirty-five patients (35 limbs) with PAD Rutherford class
III and IV underwent PQ procedure for superficial femoral
artery lesion at Pauls Stradiòð Clinical University Hospital
(Rîga, Latvia).
The Local Ethics Committee gave approval for the study.
All patients signed a consent form before the study.
Thirty-two (91.4%) patients were males and two (8.6%) fe-
males with median age 63.6 years (ranged 50 to 87 years).
Initial eligibility evaluation of patients prior to PQ proce-
dure was based on computed tomography angiography
(CTA) of abdominal aorta and lower extremity arteries as
well as arterial and venous DUS findings.
Follow-up was done using DUS and ABI determination at
30 days, 6 months, and 12 months.
All ultrasound examinations were performed using a Phil-
lips iU22 xMATRIX Ultrasound system with a L9-3 linear
transducer. B-mode ultrasound was used to evaluate stent
graft position, deformities, vein diameters, compressibility,
and leg oedema. DUS was used to evaluate haemodynamics
proximally and distally from the stent graft, as well as in
stent, vein reflux, and flow. Peak systolic velocity (PSV),
resistive index (RI), and spectral waveform were evaluated,
as well as distal blood flow in the arteries of the leg.
DUS in the prospective clinical study was conducted at one
clinical site by two independent radiologists. A result was
accepted if the differences for inter-observer PSV measure-
ment were less than 40 cm/s (Winter-Warnars et al., 1996).
The ankle-brachial index (ABI) was calculated as the ratio
of blood pressure at the ankle to the blood pressure in the
brachium (Aboyans et al., 2012). Segmental systolic pres-
sure measurement was performed, using an OMRON Vas-
cular Profiling System VP-1000 (USA).
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Fig. 1. Schematic representation of re-estab-
lished blood flow after implantation of a PQ-by-
pass endograft. The proximal segment of the
endograft is placed within SFA (1). About 4 cm
below common femoral artery bifurcation, the
endograft crosses the wall of SFA (2) and enters
the lumen of superficial femoral vein (3) to by-
pass the thrombosed arterial segment (4). Distal
to occlusion site, the endograft re-enters arterial
lumen (5) and remains fixed within a few centi-
metres of proximal popliteal artery (6), provid-
ing outflow into the intact distal popliteal artery
(7).
RESULTS
Follow-up evaluation of 35 patients (35 limbs) with PQ by-
pass was conducted at 1, 6 and 12 months after PQ proce-
dure in all patients. It included an assessment of the results
of the Rutherford score (Rutherford et al., 2005), ABI, arte-
rial and venous DUS.
According to TASC classification of PAD (Jaff et al.,
2015), the study enrolled four patients (11.4%) with TASC
B lesion, 19 (54.3%) with TASC C lesion, and 12 patients
(34.3%) with TASC D lesion, respectively.
Thirty of the study patients (85.7%) were matched to Ruth-
erford classification grade III, four (11.4%) to grade IV, and
one patient (2.9%) corresponded to Rutherford grade V.
All patients underwent ABI measurement pre- and post-op-
eratively. In four (11.4%) patients, prior to the PQ proce-
dure the ABI ranged from 0.4–0.49, in ten patients (28.6%)
from 0.5–0.59, in 13 patients (37.1%) from 0.6–0.69, in six
patients (17.1%) from 0.7–0.79, and ABI was 0.83 in one
patient (2.9%). One patient (2.9%) with severe atherosclero-
sis and type 2 diabetes had ABI 1.5.
A good result of the PQ bypass during the DUS investiga-
tion is characterised by antegrade flow inside the stent-graft
and retrograde flow next to the vein walls. A good PQ treat-
ment result also is confirmed by three-phase flow inside the
stent-graft and with no signs of significant stenosis or ob-
structions in the arterio-venous junction area of the stent-
graft (Fig. 2).
As a criteria for grading the degree of arterial narrowing
from the DUS, we used the ratio of pre-stenosis/stenosis,
proposed by Cossman et al. (1989). A velocity ratio < 1.5 :
1 corresponds to normal artery, a velocity ratio 1.5–2.1 cor-
responds to 25–50% arterial stenosis, the ratio 2–4.1 corre-
sponds to 50–75% arterial stenosis, and the ratio 4 : 1 corre-
sponds to stenosis of artery > 75%. No flow means that the
artery is closed. Twelve months after the PQ procedure, 28
PQ stent-grafts (80%) were still functioning without DUS
signs of stenosis while seven limbs (20%) experienced
varying degrees of stent malfunction.
PQ stent-graft occlusion was detected in five patients
(14.3%), one 1 (2.9%) at one-month follow-up, three (8.6%)
at six months and one (2.9%) at twelve months.
PQ stent-graft proximal junction stenosis > 50% was de-
tected in one patient (2.9%) at six months follow-up and
distal junction stenosis in one patient (2.9%) at twelve
months follow-up (Fig. 3).
In five limbs (14.3%), including two with PQ stent-graft,
previous detected stenosis and stent thrombosis developed
(Fig. 4).
All patients with PQ stent-graft stenosis were asympto-
matic. All patients with PQ stent thrombosis presented
symptoms of acute lower limb ischaemia.
During follow-up visits of patients with documented PQ
stent-graft stenosis, examination showed only a slight de-
crease of ABI (range 0.05 to 0.15) compared to the immedi-
ate post-operative result.
Despite of insignificant reduction of ABI, DUS evaluation
showed significant stenosis when even ABI results failed to
detect them.
The criteria for bypass stenosis detection are the same as for
surgical bypasses in other studies. However, these methods
cannot be compared directly because each of them has its
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Fig. 2. (A) PQ stent-graft inside a femoral vein. (B)
Fully patent PQ stent-graft’s arterio-venous junction.
The stent-graft is well defined with hyper-echoic
wall. Arterial triphasic flow is observed inside the
PQ stent-graft.
Fig. 3. DUS detects wall clot in stent,
narrowing PQ stent-graft (A) and the PQ
stent-graft proximal junction (B).
own indications and contraindications. The relatively high
number of early complications in our study is related to the
endovascular treatment of long femoral arterial occlusions
(mean 37 cm), which has not been effective in any of the
studies available to date. Endovascular treatment does not
replace classical surgical treatment. Its main advantage is
the possibility of application in situations where open surgi-
cal treatment is dangerous, or even unwanted, such as infec-
tion, severe general condition of the patient, etc. Our
method continues to evolve.
Subsequent treatment tactics in patients with PQ shunt
thrombosis include symptomatic conservative therapy, but
in cases of progression of acute limb ischaemia — open sur-
gical revascularisation.
DISCUSSION
In 2000, the first TASC meeting recommended that TASC
A lesions must be treated endovascularly, and TASC D le-
sions surgically, but no recommendation was given for
TASC B and C lesions treatment due to lack of evidence
(Dormandy et al., 2000). The BASIL trial is the only study
that has compared vein bypass and angioplasty in PAD pa-
tients with CLI (Adam et al., 2005).
With improving techniques and technologies, an increasing
number of cases may now be managed with endovascular
procedures (Jaff et al., 2015). In practical terms, although
the level of evidence is low, the initial revascularisation
strategy for femoro-popliteal disease is commonly an endo-
vascular approach, particularly for those patients with lim-
ited life expectancy (Antoniou et al., 2013).
A four-year randomised prospective comparison of
percutaneous ePTFE/Nitinol self-expanding stent graft ver-
sus prosthetic femoral-popliteal bypass in the treatment of
superficial femoral artery occlusive disease did not find any
difference between the stent graft and synthetic surgical by-
pass groups in a 1- to 4-year follow-up period in patients
with an average lesion length of 25 +/– 15 cm and TASC
scores distributed equally from A through D (McQuade et
al., 2010).
Despite lower patency in endovascular-treated TASC C/D
groups, investigators are divided on whether to recommend
surgery as the primary treatment for long-segment disease.
TASC D patients continue to have poor prognosis compared
to TASC A–C, and the patency rates for all lesion types are
better compared to stenting and PTA. In terms of TASC cat-
egories, PTA and/or stenting have outcomes equal to or
better than surgery for TASC A and B lesions, but fail to
match surgery’s patency rates in TASC C or D lesions
(Surowiec et al., 2005).
Another question to which there is still no clear answer is
whether endovascular treatment is applicable for patients
with prolonged (more than 20 cm) superficial femoral artery
occlusions. Endovascular therapy to facilitate intermittent
claudication and provide durable treatment options for
many PAD patients with CLI, and PQ stent-graft could be
one method that would help to treat these patients (Krievins
et al., 2018).
Regular clinical assessments should be carried out to assess
performance to the procedure done, the recurrence of symp-
toms and the maintenance of medical therapy. It should
however be supplemented with physiological tests, first of
all non-invasive. ABI and DUS have been identified as the
simplest and most appropriate methods capable of reliably
evaluating the results of lower limb revascularisation. It has
been proven that the durability of good surgery results is
closely associated with careful follow-up, which helps to
detect PAD progression or stent-graft restenosis in a timely
manner. ABI is inexpensive, minimally time consuming and
it is usually used as widely as DUS (Criqui et al., 2010). An
ABI of 0.90 has 75% sensitivity and 86% specificity to di-
agnose lower extremity artery disease) (Xu et al., 2013).
The ABI can easily be obtained during a physical investiga-
tion, calculating the ratio between the highest ankle pressure
measured in the dorsalis pedis artery and anterior tibial ar-
tery on each leg and the higher of two brachial pressures.
The value 0.9 corresponds to haemodynamically significant
arterial obstructive disease between the aorta and the ankle
(Aboyans et al., 2012).
ABI reductions by more than 0.15 in relation to the initial
value obtained following the procedure indicate the occur-
rence of restenosis at the intervention site or newly devel-
oped disease outside the treated segment (Sobieszczyk et
al., 2013).
Thus, as already shown, a change in ABI refers to changes
in arterial perfusion, but does not determine its location.
The extent of the reduction of the ABI when re-intervention
must be performed has not been studied as yet. Some
authors believe that a 20% reduction compared to the origi-
nal ABI immediately after the procedure leads to a thorough
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Fig. 4. PQ stent-graft thrombosis.
review of DUS and symptoms. However, it must be remem-
bered that ABI is not helpful in calcified and uncompressi-
ble vessels, which can falsely raise ABI by masking a
drop-in ankle perfusion.
Obviously, to gain confidence that the PQ shunt works in
patient undisturbed requires its visualisation.
DUS is a useful non-invasive alternative to CTA. DUS can
detect and localise vascular lesions and quantify their extent
and severity through velocity criteria (Vlachopoulos et al.,
2015). DUS presents 85–90% sensitivity and > 95% speci-
ficity to detect stenosis > 50% (Collins et al., 2007).
Clinical studies have shown that the quality of DUS de-
pends on the user’s level of experience, and that some arte-
rial segments may be visualised more readily than others,
but it still continues to play a very important role in PAD
diagnosis both before and after arterial revascularisation
(Eiberg et al., 2010).
As our study results have already shown, DUS monitoring
after PQ stent-graft implantation allows timely identifying
even a low-grade stenosis. At this stage, repeated interven-
tion can preserve the patency of the stent and prevent it
from being occluded. This is unlike ABI, which may not be
a sufficiently sensitive for assessing a low-grade stenosis,
especially if the collaterals fully mask symptoms of CLI.
Early detection of stenosis or new disease after endovascu-
lar therapy may result in less complicated re-intervention to
restore stent permeability and to prevent the development of
acute ischaemia.
Our study group of patients included mostly claudicants
with ABI > 0.4. However, even for this small CLI patient
cohort, DUS was sensitive, which was actually the main
aim of this research.
The small number of patients and events should be consid-
ered in the interpretation of results. Therefore, further stud-
ies are needed to better assess the potential of DUS in the
assessment of PAD patients after PQ stent-graft procedure.
CONCLUSIONS
DUS and ABI are recommended methods for evaluating PQ
bypass results during the follow-up period.
ABI determination is an objective, minimum time consum-
ing and non-invasive investigative method to control the
outcome of the PQ procedure. However, it may not be a suf-
ficiently sensitive for assessing a low-grade stenosis, espe-
cially if the collaterals fully mask the symptoms of lower
limb ischaemia.
DUS allows to accurately and timely identify even low-
grade stenosis of the PQ stent-graft.
Early detection of PQ stent-graft stenosis or new disease
through the DUS may result in less complicated
re-intervention to restore stent permeability and to reduce
symptoms of ischaemia.
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PQ ÐUNTÇÐANAS REZULTÂTU IZVÇRTÇÐANA AR ULTRASONODOPLEROGRÂFIJU
Pacientiem ar perifçrisko artçriju slimîbu (PAS) ir bûtiski samazinâti dzîves kvalitâtes râdîtâji. Hroniska apakðçjo ekstremitâðu iðçmija, ko
izraisa infraingvinâlo artçriju aterosklerotiski slçgumi, ir viens no bieþâkajiem invaliditâtes cçloòiem smçíçtâjiem vecumâ virs 50 gadiem.
Vçsturiski ðî patoloìija tika ârstçta, izmantojot atvçrtu íirurìisku ðuntçðanu. Mazinvazîvas endovaskularas revaskularizâcijas metodes bija
pieejamas îsâku asinsvadu slçgumu ârstçðanâ, savukârt garâkiem slçgumiem ðâdu metoþu trûkst. Pilnîbâ endovaskulâra transvenoza
femoropopliteâla ðuntçðana (PQ Bypass), kas paredzçta garu ciskas artçrijas oklûziju ârstçðanai, ieviesta nesen. Pçtîjuma mçríis bija
novçrtçt ultrasonodoplerogrâfiju (USD) kâ izmeklçðanas metodi, ar kuru varçtu sekot PQ procedûras rezultâtiem. Klîniskais pçtîjums veikts
P. Stradiòa Klîniskajâ universitâtes slimnîcâ. USD ârstçðanâ izmantotajâm artçrijâm un vçnâm veica divi neatkarîgi speciâlisti — pirms
procedûras, 30 dienas, 6 mçneðus un 12 mçneðu attâlajâ periodâ. Potîtes–augðdelma indekss (PAI) tika noteikts visas vizîtçs. Pçtîjumâ
iekïauti 35 pacienti (35 kâjas) kuri tika ârstçti, izmantojot PQ ðuntçðanu. Vidçjais pacientu vecums bija 63,6 gadi (no 50 lîdz 87 gadiem). PQ
rezultâtu kontrole veikta visiem pacientiem visâs vizîtçs. USD rezultâtu nobîde starp diviem radiologiem bija pieïaujamâs standarta robeþâs.
Divpadsmit mçneðus pçc PQ procedûras 28 (80,0%) PQ stenti joprojâm funkcionçja bez stenozes pazîmçm USD, bet septiòos (20,0%)
gadîjumos atklâta daþâdas pakâpes darbîbas traucçjumi stentâ. PQ stenta oklûzija diagnosticçta pieciem pacientiem (14,3%) – vienam
(2,9%) pirmâ mçneða kontroles vizîtç, trim (8,6%) sestâ mçneða un vienam (2,9%), attiecîgi 12. mçneða vizîtç. PQ stenta proksimâlâ
savienojuma stenoze atklâta vienam pacientam (2,9%) seðu mçneðu kontroles vizîtç bet distâlâ savienojuma stenoze vienam pacientam
(2,9%) divpadsmit mçneðu kontroles vizîtç. Neraugoties uz PQ ðunta slçgumu, kas tika diagnosticçts ar USD, diviem pacientiem netika
atrastas nopietnas PAI izmaiòas. USD ir uzticama metode PQ procedûras rezultâtu izvçrtçðanâ, un tai piemît augstâka jutîba nekâ PAI, îpaði
asimptomâtiskas PQ stenta stenozes gadîjumâ. Regulâra un savlaicîga USD izmantoðana pçcoperâcijas periodâ nodroðina savlaicîgu
potenciâlo komplikâciju atklâðanu un efektîvu ârstçðanu.
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